The week in health tech, explained in plain English.Get the free newsletter →
November 12, 2026

Takeaways from the most recent news in the technology and policies shaping healthcare.

Finance

43% of Hospitals Are Operating in the Red, Report Finds

Nearly half of US hospitals are losing money. According to Kaufman Hall's National Hospital Flash Report, released Oct. 13, 43% of hospitals operated at a loss in August as margins slipped and financial pressures intensified.

The report draws on August financial performance data from 1,300 hospitals, supplied by Strata Decision Technology, spanning all regions of the country. The core problem is familiar: costs keep climbing faster than revenue. Rising expenses, from labor to supplies to pharmaceuticals, continue to squeeze operating margins even for systems that have recovered volume.

For hospital operators, the data underscores that the post-pandemic recovery remains fragile and uneven. A growing share of hospitals operating in the red means tighter capital budgets, harder decisions on service lines and staffing, and more scrutiny on technology spending that promises efficiency. For vendors and investors, it signals continued pressure on buyers to prove near-term return on investment rather than long-horizon bets.

More in Finance

Finance

McLeod Health Operating Income Drops 9.7% as Costs Rise

McLeod Health's operating income fell 9.7% to $137.5 million in fiscal 2026 as expenses grew faster than its 8% revenue increase.

Why it matters: It shows that even revenue-growing health systems are losing margin as costs outpace reimbursement.

Finance

Novartis Lp(a) Drug Lowers Risk Marker but Fails on Outcomes

Novartis's pelacarsen lowered the cardiovascular risk marker Lp(a) but failed to reduce heart attacks or strokes, undermining a major industry strategy.

Why it matters: A failed outcomes trial for a leading Lp(a) drug threatens billions in cardiovascular research built on the assumption that lowering the marker prevents events.

Finance

Novo's Ziltivekimab Flops, But Cardiologists Stay Bullish

Novo Nordisk's ziltivekimab missed in the ZEUS cardiovascular trial, but cardiologists say the anti-inflammatory approach to heart disease remains valid.

Why it matters: Anti-inflammatory therapy is one of the biggest bets in cardiovascular medicine, and how the field reacts to a high-profile failure shapes billions in future R&D.